AstraZeneca

AstraZeneca's Phase III HIMALAYA trial of Imfinzi (durvalumab) plus Imjudo (tremelimumab) showed a 24% reduction in death risk in advanced liver cancer patients, with 19.6% surviving five years, compared to 7% historically.

The article discusses the use of SSR (Server-Side Rendering) and its entry point in a bundle, focusing on the technical aspects of web development.

AstraZeneca's Phase III NIAGARA study shows perioperative Imfinzi regimen significantly reduces risk of disease progression, recurrence, and death by 32% and 25% respectively in muscle-invasive bladder cancer patients, with no new safety signals.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.

AstraZeneca's Imfinzi shows positive results for bladder cancer; Apple receives FDA approval for hearing aid software on earbuds.

Sanofi and AstraZeneca are shipping Beyfortus doses to the U.S. ahead of the RSV season, with FDA clearance for a new manufacturing line. Despite initial supply issues, Sanofi aims to meet demand through additional production lines and a reservation system for private healthcare providers.

Sanofi is shipping BEYFORTUS doses in the US to ensure every eligible baby has access to immunization against RSV. A new filling line for BEYFORTUS has been approved by the FDA to expand manufacturing capacity. BEYFORTUS is the first long-acting monoclonal antibody for preventing RSV lower respiratory tract disease in newborns and infants up to 24 months.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account usually reactivates within 24 hours; contact support if still disabled.

Imfinzi plus Imjudo combo significantly improved five-year overall survival rates in unresectable hepatocellular carcinoma patients compared to sorafenib, with 19.6% surviving vs. 9.4%.